Emergent BioSolutions Inc. (0IGA.L)
USD 5.19
(2.98%)
USD 5.19
(2.98%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 343.9 Million USD | -31.53% |
| 2022 | 427.2 Million USD | -58.73% |
| 2021 | 1.03 Billion USD | 0.37% |
| 2020 | 1.03 Billion USD | 53.37% |
| 2019 | 672.5 Million USD | 46.16% |
| 2018 | 460.1 Million USD | 26.0% |
| 2017 | 365.16 Million USD | 2.14% |
| 2016 | 357.49 Million USD | -10.29% |
| 2015 | 398.49 Million USD | 20.13% |
| 2014 | 331.72 Million USD | 32.36% |
| 2013 | 250.61 Million USD | 6.28% |
| 2012 | 235.81 Million USD | 1.99% |
| 2011 | 231.21 Million USD | -3.28% |
| 2010 | 239.05 Million USD | 26.8% |
| 2009 | 188.52 Million USD | 30.49% |
| 2008 | 144.47 Million USD | 1.31% |
| 2007 | 142.6 Million USD | 10.89% |
| 2006 | 128.6 Million USD | 29.79% |
| 2005 | 99.08 Million USD | 85.58% |
| 2004 | 53.39 Million USD | -4.26% |
| 2003 | 55.76 Million USD | 3.33% |
| 2002 | 53.97 Million USD | 114.25% |
| 2001 | -378.79 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -54.5 Million USD | -139.1% |
| 2024 Q1 | 139.4 Million USD | 86.36% |
| 2023 Q3 | 93.7 Million USD | -36.39% |
| 2023 Q4 | 74.8 Million USD | -20.17% |
| 2023 Q2 | 147.3 Million USD | 1373.0% |
| 2023 Q1 | 10 Million USD | -91.02% |
| 2023 FY | 292.5 Million USD | -31.53% |
| 2022 Q2 | 72.9 Million USD | -51.91% |
| 2022 Q1 | 151.6 Million USD | -70.29% |
| 2022 FY | 427.2 Million USD | -58.73% |
| 2022 Q3 | 91.4 Million USD | 25.38% |
| 2022 Q4 | 111.3 Million USD | 21.77% |
| 2021 FY | 1.03 Billion USD | 0.37% |
| 2021 Q1 | 243.7 Million USD | -41.23% |
| 2021 Q2 | 169.7 Million USD | -30.37% |
| 2021 Q3 | 111.5 Million USD | -34.3% |
| 2021 Q4 | 510.3 Million USD | 357.67% |
| 2020 Q2 | 264.9 Million USD | 129.15% |
| 2020 Q3 | 236.2 Million USD | -10.83% |
| 2020 Q1 | 115.6 Million USD | -49.21% |
| 2020 Q4 | 414.7 Million USD | 75.57% |
| 2020 FY | 1.03 Billion USD | 53.37% |
| 2019 Q1 | 98.8 Million USD | -37.27% |
| 2019 FY | 672.5 Million USD | 46.16% |
| 2019 Q2 | 142.4 Million USD | 44.13% |
| 2019 Q3 | 203.8 Million USD | 43.12% |
| 2019 Q4 | 227.6 Million USD | 11.68% |
| 2018 Q3 | 100.42 Million USD | -23.36% |
| 2018 Q2 | 131.02 Million USD | 119.22% |
| 2018 FY | 460.1 Million USD | 26.0% |
| 2018 Q1 | 59.77 Million USD | -51.62% |
| 2018 Q4 | 157.5 Million USD | 56.84% |
| 2017 Q2 | 66.14 Million USD | -6.22% |
| 2017 FY | 365.16 Million USD | 2.14% |
| 2017 Q1 | 70.53 Million USD | -37.8% |
| 2017 Q4 | 123.55 Million USD | 17.74% |
| 2017 Q3 | 104.93 Million USD | 58.63% |
| 2016 Q3 | 103.35 Million USD | 56.89% |
| 2016 Q1 | 82.49 Million USD | -35.72% |
| 2016 FY | 357.49 Million USD | -10.29% |
| 2016 Q4 | 113.4 Million USD | 9.72% |
| 2016 Q2 | 65.87 Million USD | -20.15% |
| 2015 FY | 398.49 Million USD | 20.13% |
| 2015 Q4 | 128.33 Million USD | 1.51% |
| 2015 Q3 | 126.42 Million USD | 27.91% |
| 2015 Q2 | 98.84 Million USD | 120.22% |
| 2015 Q1 | 44.88 Million USD | -61.14% |
| 2014 Q3 | 105.53 Million USD | 39.19% |
| 2014 Q4 | 115.49 Million USD | 9.44% |
| 2014 FY | 331.72 Million USD | 32.36% |
| 2014 Q1 | 34.88 Million USD | -55.66% |
| 2014 Q2 | 75.81 Million USD | 117.32% |
| 2013 Q3 | 69.03 Million USD | 5.42% |
| 2013 FY | 250.61 Million USD | 6.28% |
| 2013 Q1 | 37.4 Million USD | -52.93% |
| 2013 Q4 | 78.68 Million USD | 13.97% |
| 2013 Q2 | 65.49 Million USD | 75.1% |
| 2012 FY | 235.81 Million USD | 1.99% |
| 2012 Q4 | 79.45 Million USD | 40.97% |
| 2012 Q3 | 56.36 Million USD | -1.45% |
| 2012 Q2 | 57.19 Million USD | 33.63% |
| 2012 Q1 | 42.8 Million USD | -54.28% |
| 2011 Q4 | 93.62 Million USD | 94.81% |
| 2011 Q1 | 17.46 Million USD | -79.75% |
| 2011 Q2 | 72.07 Million USD | 312.67% |
| 2011 Q3 | 48.05 Million USD | -33.32% |
| 2011 FY | 231.21 Million USD | -3.28% |
| 2010 Q2 | 51.06 Million USD | 29.96% |
| 2010 Q1 | 39.29 Million USD | -6.5% |
| 2010 Q3 | 62.45 Million USD | 22.31% |
| 2010 Q4 | 86.24 Million USD | 38.1% |
| 2010 FY | 239.05 Million USD | 26.8% |
| 2009 Q2 | 62.76 Million USD | 27.69% |
| 2009 FY | 188.52 Million USD | 30.49% |
| 2009 Q4 | 42.02 Million USD | 21.49% |
| 2009 Q3 | 34.58 Million USD | -44.89% |
| 2009 Q1 | 49.15 Million USD | 70.19% |
| 2008 Q1 | 34.71 Million USD | -51.85% |
| 2008 FY | 144.47 Million USD | 1.31% |
| 2008 Q4 | 28.88 Million USD | -37.33% |
| 2008 Q3 | 46.08 Million USD | 32.4% |
| 2008 Q2 | 34.8 Million USD | 0.27% |
| 2007 Q3 | 32.23 Million USD | 85.87% |
| 2007 Q4 | 72.09 Million USD | 123.63% |
| 2007 Q1 | 20.93 Million USD | -71.87% |
| 2007 FY | 142.6 Million USD | 10.89% |
| 2007 Q2 | 17.34 Million USD | -17.14% |
| 2006 Q3 | 18.06 Million USD | -17.69% |
| 2006 Q4 | 74.4 Million USD | 311.87% |
| 2006 FY | 128.6 Million USD | 29.79% |
| 2006 Q2 | 21.94 Million USD | 0.0% |
| 2006 Q1 | 21.94 Million USD | -49.88% |
| 2005 Q3 | 28.96 Million USD | 0.0% |
| 2005 Q2 | 28.96 Million USD | 0.0% |
| 2005 Q1 | 28.96 Million USD | 38.78% |
| 2005 FY | 99.08 Million USD | 85.58% |
| 2005 Q4 | 43.78 Million USD | 51.17% |
| 2004 Q3 | 20.87 Million USD | 0.0% |
| 2004 Q1 | 20.87 Million USD | 0.0% |
| 2004 Q2 | 20.87 Million USD | 0.0% |
| 2004 FY | 53.39 Million USD | -4.26% |
| 2004 Q4 | 20.87 Million USD | -0.0% |
| 2003 FY | 55.76 Million USD | 3.33% |
| 2002 FY | 53.97 Million USD | 114.25% |
| 2001 Q1 | 227.2 Million USD | 39.05% |
| 2001 Q2 | 203 Million USD | -10.65% |
| 2001 Q3 | 225.8 Million USD | 11.23% |
| 2001 FY | -378.79 Million USD | 0.0% |
| 2001 Q4 | 163.4 Million USD | -27.64% |
| 2000 Q4 | 163.4 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -15425.959% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -113774.172% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 503.563% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -1885.68% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 109972.204% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -2224.591% |
| Imunon, Inc. | -720 Thousand USD | 47863.557% |
| Dynavax Technologies Corporation | 182.11 Million USD | -88.835% |
| Editas Medicine, Inc. | -99.52 Million USD | 445.531% |
| FibroGen, Inc. | 128.9 Million USD | -166.788% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 3695.024% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 113598.35% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 81.385% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 68.536% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 34.338% |
| Verastem, Inc. | -62 Thousand USD | 554777.419% |
| Zoetis Inc. | 5.83 Billion USD | 94.105% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 96.004% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 858.742% |
| Homology Medicines, Inc. | -7.22 Million USD | 4857.228% |
| Nektar Therapeutics | 53.47 Million USD | -543.068% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 117873.973% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 1845.774% |
| Perrigo Company plc | 1.68 Billion USD | 79.535% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -370.664% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.703% |
| Illumina, Inc. | 2.74 Billion USD | 87.467% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 97.741% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 93.436% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -3324.617% |
| Waters Corporation | 1.76 Billion USD | 80.473% |
| Biogen Inc. | 7.3 Billion USD | 95.29% |
| Evolus, Inc. | 140.52 Million USD | -144.723% |
| Adicet Bio, Inc. | -6.09 Million USD | 5739.554% |
| bluebird bio, Inc. | -4.03 Million USD | 8633.499% |
| Geron Corporation | -123.5 Million USD | 378.455% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 77.343% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 5.008% |
| Myriad Genetics, Inc. | 476.4 Million USD | 27.813% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 186.235% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 84.145% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1203.387% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 81.942% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 96.957% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 90.075% |
| OPKO Health, Inc. | 318.12 Million USD | -8.101% |
| Exelixis, Inc. | 1.75 Billion USD | 80.434% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 27.736% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -40.634% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 55.826% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 46.003% |
| Blueprint Medicines Corporation | 236.58 Million USD | -45.361% |
| Insmed Incorporated | 239.63 Million USD | -43.51% |
| TG Therapeutics, Inc. | 219.1 Million USD | -56.955% |
| Incyte Corporation | 3.44 Billion USD | 90.005% |